Review and evaluation of sentinel node procedures in 250 melanoma patients with a median follow-up of 6 years

被引:119
作者
Estourgie, SH
Nieweg, OE
Olmos, RAV
Hoefnagel, CA
Kroon, BBR
机构
[1] Antoni Van Leeuwenhoek Hosp, Netherlands Canc Inst, Dept Surg, NL-1066 CX Amsterdam, Netherlands
[2] Antoni Van Leeuwenhoek Hosp, Netherlands Canc Inst, Dept Nucl Med, NL-1066 CX Amsterdam, Netherlands
关键词
analysis; melanoma; morbidity; recurrence; sentinel node; survival;
D O I
10.1245/ASO.2003.01.023
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The aim of this study was to evaluate the results of sentinel node biopsy in cutaneous melanoma at our institute. Methods: A total of 250 patients with cutaneous melanoma were studied prospectively. Preoperative lymphoscintigraphy was performed after injection of Tc-99m-nanocolloid intradermally around the primary tumor or biopsy site (.32 mL, 65.5 MBq [1.8 mCi]). The sentinel node was surgically identified with the aid of patent blue dye and a gamma ray detection probe. The median follow-up was 72 months. Results: Lymphoscintigraphic visualization was 100%, and surgical identification was 99.6%. In 60 patients (24%), 1 or more sentinel nodes were tumor positive at initial pathology evaluation. Late complications after sentinel node biopsy of the remaining 190 patients were seen in 35 patients (18%). The false-negative rate was 9%. In-transit metastases were seen in 7% of sentinel nodenegative and 23% of sentinel node-positive patients. The estimated 5-year overall survival rates were 89% and 64%, respectively (P < .001). Conclusions: This study confirms that the status of the sentinel node is a strong independent prognostic factor. The false-negative rate and the incidence of in-transit metastases in sentinel node-positive patients are high and have to be weighed against the possible survival benefit of early removal of nodal metastases.
引用
收藏
页码:681 / 688
页数:8
相关论文
共 39 条
[1]   Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm) [J].
Balch, CM ;
Soong, SJ ;
Ross, MI ;
Urist, MM ;
Karakousis, CP ;
Temple, WJ ;
Mihm, MC ;
Barnhill, RL ;
Jewell, WR ;
Wanebo, HJ ;
Harrison, R .
ANNALS OF SURGICAL ONCOLOGY, 2000, 7 (02) :87-97
[2]  
CALABRO A, 1989, ARCH SURG-CHICAGO, V124, P1051
[3]   Sentinel lymph node biopsy in cutaneous melanoma: The WHO Melanoma Program experience [J].
Cascinelli, N ;
Belli, F ;
Santinami, M ;
Fait, V ;
Testori, A ;
Ruka, W ;
Cavaliere, R ;
Mozzillo, N ;
Rossi, CR ;
MacKie, RM ;
Nieweg, O ;
Pace, M ;
Kirov, K .
ANNALS OF SURGICAL ONCOLOGY, 2000, 7 (06) :469-474
[4]   Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial [J].
Cascinelli, N ;
Morabito, A ;
Santinami, M ;
MacKie, RM ;
Belli, F .
LANCET, 1998, 351 (9105) :793-796
[5]   Allergic reactions to isosulfan blue during sentinel node biopsy - a common event [J].
Cimmino, VM ;
Brown, AC ;
Szocik, JF ;
Pass, HA ;
Moline, S ;
De, SK ;
Domino, EF .
SURGERY, 2001, 130 (03) :439-442
[6]   Early recurrence after lymphatic mapping and sentinel node biopsy in patients with primary extremity melanoma: A comparison with elective lymph node dissection [J].
Clary, BM ;
Mann, B ;
Brady, MS ;
Lewis, JJ ;
Coit, DG .
ANNALS OF SURGICAL ONCOLOGY, 2001, 8 (04) :328-337
[7]   Sentinel lymph node biopsy in the management of patients with primary cutaneous melanoma: Review of a large single-institutional experience with an emphasis on recurrence [J].
Clary, BM ;
Brady, MS ;
Lewis, JJ ;
Coit, DG .
ANNALS OF SURGERY, 2001, 233 (02) :250-258
[8]  
Cochran AJ, 2000, CANCER, V89, P236, DOI 10.1002/1097-0142(20000715)89:2<236::AID-CNCR5>3.0.CO
[9]  
2-0
[10]   Improved staging of node-negative patients with intermediate to thick melanomas (&gt;1 mm) with the use of lymphatic mapping and sentinel lymph node biopsy [J].
Dessureault, S ;
Soong, SJ ;
Ross, MI ;
Thompson, JF ;
Kirkwood, JM ;
Coit, DG ;
McMasters, KM ;
Balch, CM ;
Reintgen, D .
ANNALS OF SURGICAL ONCOLOGY, 2001, 8 (10) :766-770